NO851235L - Renset rekombinant interleukin-2 og fremstilling og rensing derav - Google Patents

Renset rekombinant interleukin-2 og fremstilling og rensing derav

Info

Publication number: NO851235L
Authority: NO; Norway
Prior art keywords: approx; solution; agent; sds; gel filtration
Prior art date: 1984-03-28

Application number

NO851235A

Other languages

English (en)

Norwegian (no)

Inventor

Kirston Koths

James William Thomson

Michael Kunitani

Kenneth Wilson

Wolfgang Helmut Hanisch

Original Assignee

Cetus Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-03-28

Filing date

1985-03-27

Publication date

1985-09-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24378044&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO851235(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1985-03-27 Application filed by Cetus Corp filed Critical Cetus Corp

1985-09-30 Publication of NO851235L publication Critical patent/NO851235L/no

Links

108010002350 Interleukin-2 Proteins 0.000 title claims abstract description 108
102000000588 Interleukin-2 Human genes 0.000 title claims description 103
238000002360 preparation method Methods 0.000 title claims 4
238000004140 cleaning Methods 0.000 title 1
238000000034 method Methods 0.000 claims abstract description 43
239000000243 solution Substances 0.000 claims abstract description 31
238000000605 extraction Methods 0.000 claims abstract description 23
238000004007 reversed phase HPLC Methods 0.000 claims abstract description 23
239000002904 solvent Substances 0.000 claims abstract description 22
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 18
BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 claims abstract description 18
244000005700 microbiome Species 0.000 claims abstract description 17
MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 claims abstract description 15
239000003638 chemical reducing agent Substances 0.000 claims abstract description 13
239000000463 material Substances 0.000 claims abstract description 13
239000007864 aqueous solution Substances 0.000 claims abstract description 12
239000000203 mixture Substances 0.000 claims abstract description 12
230000008569 process Effects 0.000 claims abstract description 11
239000004202 carbamide Substances 0.000 claims abstract description 10
239000003795 chemical substances by application Substances 0.000 claims abstract description 10
239000007790 solid phase Substances 0.000 claims abstract description 9
238000001641 gel filtration chromatography Methods 0.000 claims abstract description 8
230000003196 chaotropic effect Effects 0.000 claims abstract description 7
239000000284 extract Substances 0.000 claims abstract description 6
230000003381 solubilizing effect Effects 0.000 claims abstract description 5
210000000170 cell membrane Anatomy 0.000 claims abstract description 4
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 23
238000002523 gelfiltration Methods 0.000 claims description 14
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 12
210000004027 cell Anatomy 0.000 claims description 11
239000002158 endotoxin Substances 0.000 claims description 9
238000000746 purification Methods 0.000 claims description 6
238000004458 analytical method Methods 0.000 claims description 5
230000001698 pyrogenic effect Effects 0.000 claims description 3
241000283973 Oryctolagus cuniculus Species 0.000 claims description 2
238000003916 acid precipitation Methods 0.000 claims description 2
238000011046 pyrogen test Methods 0.000 claims description 2
ADWNFGORSPBALY-UHFFFAOYSA-M sodium;2-[dodecyl(methyl)amino]acetate Chemical compound [Na+].CCCCCCCCCCCCN(C)CC([O-])=O ADWNFGORSPBALY-UHFFFAOYSA-M 0.000 claims description 2
239000000126 substance Substances 0.000 claims description 2
108090000623 proteins and genes Proteins 0.000 abstract description 29
102000004169 proteins and genes Human genes 0.000 abstract description 29
230000001413 cellular effect Effects 0.000 abstract description 11
230000000813 microbial effect Effects 0.000 abstract 1
230000001590 oxidative effect Effects 0.000 abstract 1
235000018102 proteins Nutrition 0.000 description 28
241000588724 Escherichia coli Species 0.000 description 16
239000000047 product Substances 0.000 description 16
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 14
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 12
239000000872 buffer Substances 0.000 description 11
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 9
150000001413 amino acids Chemical class 0.000 description 9
108700004121 sarkosyl Proteins 0.000 description 9
229940016590 sarkosyl Drugs 0.000 description 9
KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 9
239000000725 suspension Substances 0.000 description 9
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
239000007983 Tris buffer Substances 0.000 description 7
239000000356 contaminant Substances 0.000 description 7
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 7
230000000694 effects Effects 0.000 description 7
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 7
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
235000018417 cysteine Nutrition 0.000 description 6
239000007791 liquid phase Substances 0.000 description 6
238000000926 separation method Methods 0.000 description 6
238000005063 solubilization Methods 0.000 description 6
230000007928 solubilization Effects 0.000 description 6
GONSYFXEPMZGNN-UHFFFAOYSA-N acetic acid;propan-1-ol Chemical compound CCCO.CC(O)=O GONSYFXEPMZGNN-UHFFFAOYSA-N 0.000 description 5
238000005119 centrifugation Methods 0.000 description 5
239000001963 growth medium Substances 0.000 description 5
239000002609 medium Substances 0.000 description 5
239000012071 phase Substances 0.000 description 5
238000004587 chromatography analysis Methods 0.000 description 4
102000055277 human IL2 Human genes 0.000 description 4
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
238000007792 addition Methods 0.000 description 3
235000001014 amino acid Nutrition 0.000 description 3
239000012062 aqueous buffer Substances 0.000 description 3
239000012736 aqueous medium Substances 0.000 description 3
239000000969 carrier Substances 0.000 description 3
239000012141 concentrate Substances 0.000 description 3
239000000287 crude extract Substances 0.000 description 3
239000000499 gel Substances 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
IFPHDUVGLXEIOQ-UHFFFAOYSA-N ortho-iodosylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I=O IFPHDUVGLXEIOQ-UHFFFAOYSA-N 0.000 description 3
238000007254 oxidation reaction Methods 0.000 description 3
239000011236 particulate material Substances 0.000 description 3
239000000523 sample Substances 0.000 description 3
238000003756 stirring Methods 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 2
241001646716 Escherichia coli K-12 Species 0.000 description 2
230000005526 G1 to G0 transition Effects 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 2
235000004279 alanine Nutrition 0.000 description 2
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
229960003067 cystine Drugs 0.000 description 2
239000003599 detergent Substances 0.000 description 2
238000010586 diagram Methods 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
-1 energy sources Chemical compound 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000008103 glucose Substances 0.000 description 2
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
238000000265 homogenisation Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
239000002198 insoluble material Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
ZIHBOROHTYWINY-UHFFFAOYSA-N propan-1-ol;2,2,2-trifluoroacetic acid Chemical compound CCCO.OC(=O)C(F)(F)F ZIHBOROHTYWINY-UHFFFAOYSA-N 0.000 description 2
239000002510 pyrogen Substances 0.000 description 2
238000011084 recovery Methods 0.000 description 2
230000009467 reduction Effects 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
229910000162 sodium phosphate Inorganic materials 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000000527 sonication Methods 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
238000000108 ultra-filtration Methods 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
HRNGDAQBEIFYGL-UHFFFAOYSA-N 3,4-dihydroxy-4-tetradeca-3,6-dienoyloxybutanoic acid Chemical compound CCCCCCCC=CCC=CCC(=O)OC(O)C(O)CC(O)=O HRNGDAQBEIFYGL-UHFFFAOYSA-N 0.000 description 1
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
238000011050 LAL assay Methods 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241001529936 Murinae Species 0.000 description 1
101100400378 Mus musculus Marveld2 gene Proteins 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
208000010362 Protozoan Infections Diseases 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
239000012506 Sephacryl® Substances 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052936 alkali metal sulfate Inorganic materials 0.000 description 1
230000000961 alloantigen Effects 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
239000002585 base Substances 0.000 description 1
238000010923 batch production Methods 0.000 description 1
238000010364 biochemical engineering Methods 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000011210 chromatographic step Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
230000001351 cycling effect Effects 0.000 description 1
238000011026 diafiltration Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
239000003480 eluent Substances 0.000 description 1
239000003344 environmental pollutant Substances 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
102000035122 glycosylated proteins Human genes 0.000 description 1
108091005608 glycosylated proteins Proteins 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
239000012510 hollow fiber Substances 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
210000003000 inclusion body Anatomy 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000012933 kinetic analysis Methods 0.000 description 1
239000013541 low molecular weight contaminant Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910001425 magnesium ion Inorganic materials 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
239000011368 organic material Substances 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
230000003071 parasitic effect Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
231100000719 pollutant Toxicity 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910001414 potassium ion Inorganic materials 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000009696 proliferative response Effects 0.000 description 1
230000006920 protein precipitation Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000012552 review Methods 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
229910001415 sodium ion Inorganic materials 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
General Engineering & Computer Science (AREA)
Analytical Chemistry (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Toxicology (AREA)
Wood Science & Technology (AREA)
Gastroenterology & Hepatology (AREA)
Biomedical Technology (AREA)
Animal Behavior & Ethology (AREA)
Physics & Mathematics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Plant Pathology (AREA)
Pharmacology & Pharmacy (AREA)
Microbiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

NO851235A 1984-03-28 1985-03-27 Renset rekombinant interleukin-2 og fremstilling og rensing derav NO851235L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US06/594,223 US4569790A (en)	1984-03-28	1984-03-28	Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions

Publications (1)

Publication Number	Publication Date
NO851235L true NO851235L (no)	1985-09-30

Family

ID=24378044

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO851235A NO851235L (no)	1984-03-28	1985-03-27	Renset rekombinant interleukin-2 og fremstilling og rensing derav

Country Status (20)

Country	Link
US (3)	US4569790A (de)
EP (2)	EP0156373B1 (de)
JP (2)	JP2599903B2 (de)
KR (1)	KR850007083A (de)
AT (1)	ATE81674T1 (de)
AU (1)	AU592751B2 (de)
CA (1)	CA1341083C (de)
DE (2)	DE3588189T2 (de)
DK (1)	DK166324C (de)
ES (1)	ES8609362A1 (de)
FI (1)	FI94960C (de)
GR (1)	GR850741B (de)
IE (1)	IE59100B1 (de)
IL (1)	IL74733A (de)
IN (1)	IN162903B (de)
NO (1)	NO851235L (de)
NZ (1)	NZ211569A (de)
PH (1)	PH21012A (de)
PT (1)	PT80172B (de)
ZA (1)	ZA852347B (de)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4925919A (en) *	1984-04-25	1990-05-15	Roland Mertelsmann	Purified interleukin 2
US4992271A (en) *	1982-09-23	1991-02-12	Cetus Corporation	Formulation for lipophilic IL-2 proteins
US4853332A (en) *	1982-10-19	1989-08-01	Cetus Corporation	Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
JPS60115528A (ja) *	1983-11-28	1985-06-22	Takeda Chem Ind Ltd	ヒトインタ―ロイキン―２蛋白質を含有する抗腫瘍用または免疫機能低下疾患治療用組成物
DK174501B1 (da) *	1983-12-23	2003-04-28	Hoffmann La Roche	Fremgangsmåde til fremstilling af interleukin-2
US4656132A (en) *	1984-03-28	1987-04-07	Cetus Corporation	Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria
US4530787A (en) *	1984-03-28	1985-07-23	Cetus Corporation	Controlled oxidation of microbially produced cysteine-containing proteins
US4569790A (en) *	1984-03-28	1986-02-11	Cetus Corporation	Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
DE3583880D1 (de) *	1984-04-09	1991-10-02	Takeda Chemical Industries Ltd	Stabile interleukin-2-zusammensetzung.
US4908434A (en) *	1984-04-25	1990-03-13	Sloan-Kettering Institute For Cancer Research	Process for preparing purified interleukin-2
US4908433A (en) *	1984-04-25	1990-03-13	Sloan-Kettering Institute For Cancer Research	Uses of interleukin-2
US4572798A (en) *	1984-12-06	1986-02-25	Cetus Corporation	Method for promoting disulfide bond formation in recombinant proteins
DE3500681A1 (de) *	1985-01-11	1986-07-17	Hoechst Ag, 6230 Frankfurt	Verfahren zur isolierung und reinigung von lymphokinen
JPH0646957B2 (ja) *	1985-03-11	1994-06-22	武田薬品工業株式会社	インタ−ロイキン−２の製造方法
US5523215A (en) *	1985-03-28	1996-06-04	Chiron Corporation	Enhanced purification and expression of insoluble recombinant proteins
US4748234A (en) *	1985-06-26	1988-05-31	Cetus Corporation	Process for recovering refractile bodies containing heterologous proteins from microbial hosts
US5248769A (en) *	1985-06-26	1993-09-28	Cetus Oncology Corporation	Process for recovering refractile bodies containing heterologous proteins from microbial hosts
US4788144A (en) *	1985-06-28	1988-11-29	International Minerals & Chemical Corp.	Fermentation process for the high level production of swine growth
US4762784A (en) *	1985-07-15	1988-08-09	International Minerals & Chemical Corp.	Fermemtation process for the high level production of bovine growth hormone
US4690915A (en) *	1985-08-08	1987-09-01	The United States Of America As Represented By The Department Of Health And Human Services	Adoptive immunotherapy as a treatment modality in humans
CA1297003C (en) *	1985-09-20	1992-03-10	Jack H. Nunberg	Composition and method for treating animals
US4766205A (en) *	1985-11-13	1988-08-23	Beatrice Companies, Inc.	Method for isolation of recombinant polypeptides in biologically active forms
US4933433A (en) *	1986-01-31	1990-06-12	E. I. Du Pont De Nemours And Company	Recombinant interleukin-2 composition and process for making it
US5425940A (en) *	1986-04-09	1995-06-20	Cetus Oncology Corporation	Combination therapy using interleukin-2 and tumor necrosis factor
US4931544A (en) *	1986-09-04	1990-06-05	Cetus Corporation	Succinylated interleukin-2 for pharmaceutical compositions
US4683293A (en) *	1986-10-20	1987-07-28	Phillips Petroleum Company	Purification of pichia produced lipophilic proteins
US4894330A (en) *	1986-12-23	1990-01-16	Cetus Corporation	Purification of recombinant beta-interferon incorporating RP-HPLC
US4879374A (en) *	1987-03-13	1989-11-07	Immunex Corporation	Bovine interleukin-1β DNA sequence
US5108911A (en) *	1987-03-13	1992-04-28	Immunex Corporation	Process for preparing bovine interleukin-Iβ
CA1339757C (en) *	1987-04-16	1998-03-17	Robert F. Halenbeck	Production of purified biologically active, bacterially produced recombinant human csf-1
US4929700A (en) *	1987-04-16	1990-05-29	Cetus Corporation	Production of purified, biologically active, bacterially produced recombinant human CSF-1
JPS6463395A (en)	1987-05-04	1989-03-09	Oncogen	Oncostatin m and novel composition having antitumor activity
US4931543A (en) *	1987-05-11	1990-06-05	Cetus Corporation	Process for recovering microbially produced interleukin-2
ATE156491T1 (de) *	1987-05-11	1997-08-15	Chiron Corp	Prozess zur gewinnung von gereinigtem, oxidiertem, renaturiertem, rekombinantem interleukin-2 aus mikroorganismen
US5162507A (en) *	1987-05-11	1992-11-10	Cetus Corporation	Process for recovering purified, oxidized, renatured recombinant interleukin-2 from microorganisms
US4801691A (en) *	1987-05-15	1989-01-31	International Minerals & Chemical Corp.	Method for removing sodium dodecyl sulfate from sodium dodecyl sulfate solubilized protein solutions
KR890701759A (ko) *	1987-07-29	1989-12-21	스테이너 브이. 칸스태드	에스케리키아 콜라이내에서 발현된 사람 인터루킨-4의 정제방법
JP2669859B2 (ja) *	1987-08-04	1997-10-29	協和醗酵工業株式会社	タンパク質の再活性化法
EP0337243A1 (de) *	1988-04-14	1989-10-18	F. Hoffmann-La Roche Ag	Verfahren zur Reinigung von rekombinantem Interleukin-2
FR2635527B1 (fr) *	1988-07-28	1992-06-12	Roussel Uclaf	Il2 humaine recombinante non glycosylee sous forme reduite, son procede d'obtention et son application comme medicament
US4923967A (en) *	1988-09-26	1990-05-08	Eli Lilly And Company	Purification and refolding of recombinant proteins
US5830452A (en) *	1990-11-20	1998-11-03	Chiron Corporation	Method for enhancing the anti-tumor therapeutic index of interleukin-2
ATE159260T1 (de) *	1990-11-23	1997-11-15	Roussel Uclaf	Verfahren zur herstellung eines proteins gehörend zu der klasse der cytokine, das mindestens eine intramolekulare disulfidbrücke enthält, durch oxidation bei einem ph-wert kleiner als 5.0 des entsprechenden rekombinanten reduzierten proteins
US5939524A (en) *	1991-12-09	1999-08-17	The Scripps Research Institute	Platelet GPIII P1A1 and P1A2 epitopes, their preparation and use
AU648214B2 (en) *	1991-12-31	1994-04-14	Lucky Limited	Recombinant gene coding for human alpha interferon and expression vector thereof, etc.
FR2686899B1 (fr) *	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6063764A (en) *	1992-06-01	2000-05-16	Washington University & Chiron Corp.	Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US20030171292A1 (en) *	1992-06-01	2003-09-11	Creasey Abla A.	Method for using lipoprotein associated coagulation inhibitor to treat sepsis
AU687763B2 (en) *	1992-10-20	1998-03-05	Central Laboratory Of The Netherlands Red Cross Blood Transfusion Service	Interleukin-6 receptor antagonists
CN1051092C (zh) *	1993-05-21	2000-04-05	沈阳军区后勤部军事医学研究所	一种重组大肠杆菌培养液中分离和纯化重组人白细胞介素2的方法
US5632983A (en)	1994-11-17	1997-05-27	University Of South Florida	Method for treating secondary immunodeficiency
US5912327A (en) *	1996-09-30	1999-06-15	Human Genome Sciences, Inc.	Method of purifying chemokines from inclusion bodies
US6632425B1 (en)	1997-03-20	2003-10-14	Human Genome Sciences, Inc.	Chemokine compositions
EP1935431A3 (de)	2000-05-15	2008-08-13	Health Research, Inc.	Krebsbehandlungen unter Verwendung einer Kombination aus einem HER2-Antikörper und Interleukin-2
JP4303969B2 (ja)	2001-03-29	2009-07-29	シェーリングコーポレイション	Ｃｃｒ５アンタゴニストとして有用なアリールオキシム−ピペラジン
US7674769B2 (en) *	2001-10-15	2010-03-09	Novartis Vaccines And Diagnostics, Inc.	Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (TFPI)
WO2003099320A1 (en)	2002-05-24	2003-12-04	Zensun (Shanghai) Sci-Tech.Ltd	Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
BRPI0408704A (pt)	2003-03-24	2006-03-07	Hoffmann La Roche	benzil-piridazinonas como inibidores de transcriptase reversa
JP4642025B2 (ja) *	2003-09-09	2011-03-02	ノバルティスバクシンズアンドダイアグノスティックス，インコーポレーテッド	治療的ポリペプチドのクロマトグラフィー分離
BRPI0415771A (pt)	2003-10-23	2006-12-26	Illumigen Biosciences Inc	detecção de mutações em um gene associado à resistência a infecção viral, oas1
ATE473016T1 (de)	2003-11-04	2010-07-15	Novartis Vaccines & Diagnostic	Verfahren zur behandlung von krebs mit expression des cd40-antigens
CN101426520A (zh) *	2004-03-17	2009-05-06	诺华疫苗和诊断公司	通过给予组织因子途径抑制剂（tfpi）治疗社区获得性重症肺炎
CU23297A1 (es)	2004-11-16	2008-07-24	Ct De Inmunologa A Molecular	Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
DE102005005542A1 (de) *	2005-02-07	2006-08-10	Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville	Herstellung von Aldesleukin für die pharmazeutische Verwendung
WO2007045573A1 (en)	2005-10-19	2007-04-26	F. Hoffmann-La Roche Ag	Phenyl-acetamide nnrt inhibitors
RU2304586C1 (ru) *	2006-03-27	2007-08-20	Михаил Николаевич Смирнов	Препарат интерлейкина-2 и способ его получения
BRPI0715193A2 (pt)	2006-08-16	2013-10-01	Hoffmann La Roche	inibidores nço-nucleosÍdicos da transcriptase reversa
JP5415957B2 (ja)	2006-12-13	2014-02-12	エフ．ホフマン−ラロシュアーゲー	非ヌクレオシド逆転写酵素阻害剤としての２−（ピペリジン−４−イル）−４−フェノキシ−又はフェニルアミノ−ピリミジン誘導体
AU2008257771B2 (en)	2007-05-30	2015-02-19	F. Hoffmann-La Roche Ag	Non-nucleoside reverse transcriptase inhibitors
CN101903382B (zh)	2007-12-21	2012-11-28	弗·哈夫曼-拉罗切有限公司	杂环抗病毒化合物
BRPI0917961A2 (pt) *	2008-08-04	2017-04-11	Kai Bioenergy	cultivo, colheita e extração contínua de óleo de culturas fotossintéticas
HRP20210642T1 (hr)	2010-11-12	2021-05-28	Nektar Therapeutics	Konjugati il-2 ostatka i polimera
US9428567B2 (en)	2010-12-22	2016-08-30	The Board Of Trustees Of The Leland Stanford Junior University	Antagonists of interleukin-2 receptor
WO2013180650A1 (en) *	2012-05-31	2013-12-05	Agency For Science, Technology And Research	Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives
CA2925421C (en)	2013-09-24	2023-08-29	Medicenna Therapeutics, Inc.	Interleukin-2 fusion proteins and uses thereof
WO2015164815A1 (en)	2014-04-24	2015-10-29	The Board Of Trustees Of The Leland Stanford Junior University	Superagonists, partial agonists and antagonists of interleukin-2
WO2016057651A1 (en)	2014-10-09	2016-04-14	Dana-Farber Cancer Institute, Inc.	Multiple-variable il-2 dose regimen for treating immune disorders
KR102861230B1 (ko)	2015-10-08	2025-09-17	넥타르 테라퓨틱스	Il-2r베타-선택적 효현제 및 지속 작용성 il-15 효현제의 조합
JP7433051B2 (ja)	2017-06-19	2024-02-19	メディシナセラピューティクスインコーポレイテッド	Ｉｌ－２スーパーアゴニスト、アゴニスト、およびそれらの融合体の使用および方法
CA3069321A1 (en)	2017-07-11	2019-01-17	The Scripps Research Institute	Incorporation of unnatural nucleotides and methods thereof
KR20250145137A (ko)	2017-08-03	2025-10-13	신톡스, 인크.	자가면역 질환의 치료를 위한 사이토카인 접합체
PH12020550661A1 (en)	2017-11-21	2021-04-19	Univ Leland Stanford Junior	Partial agonists of interleukin-2
JOP20200290A1 (ar)	2018-05-21	2020-11-15	Nektar Therapeutics	تركيبة RUR20kD-IL-2 الانتقائية لمحفز TREG وتركيبات ذات صلة
CA3103603A1 (en) *	2018-06-13	2019-12-19	Akron Biotechnology, LLC.	Method to prepare therapeutically active aldesleukin highly stable in liquid pharmaceutical compositions
SG11202107354WA (en)	2019-02-06	2021-08-30	Synthorx Inc	Il-2 conjugates and methods of use thereof
CN114245802B (zh)	2019-06-20	2024-10-15	石药集团巨石生物制药有限公司	修饰的il-2蛋白、peg偶联物及其用途
EP4090674A4 (de)	2020-01-14	2024-01-24	Synthekine, Inc.	Vorgespannte il2-muteins-verfahren und -zusammensetzungen
CN111676261A (zh) *	2020-06-24	2020-09-18	宁波博睿瀚达生物科技有限公司	一种高纯度重组白介素-2的制备工艺
CN111793124A (zh) *	2020-06-24	2020-10-20	宁波博睿瀚达生物科技有限公司	一种去除重组白介素-2内毒素的方法
WO2023114833A1 (en)	2021-12-14	2023-06-22	Eli Lilly And Company	Dosing regimens for selective treg stimulator rur20kd-il-2 and related compositions

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3897309A (en) *	1974-02-15	1975-07-29	Merck & Co Inc	Process for removing pyrogenic material from aqueous solutions
JPS6030291B2 (ja) *	1978-03-20	1985-07-16	森永乳業株式会社	人顆粒球の分化増殖を促進するｈｇｉ糖蛋白質、ｈｇｉ糖蛋白質の製造法及びｈｇｉ糖蛋白質を含有する白血球減少症治療剤
IN150740B (de) *	1978-11-24	1982-12-04	Hoffmann La Roche
JPS55148098A (en) *	1979-05-10	1980-11-18	Toray Ind Inc	Concentration and purification of interferon
CH648331A5 (de) *	1979-07-31	1985-03-15	Hoffmann La Roche	Homogenes fibroblasten-interferon und dessen herstellung.
US4390623A (en) *	1980-10-02	1983-06-28	Hooper Trading Company	Serum-free and mitogen-free T-cell growth factor and process for making same
US4315852A (en) *	1980-11-26	1982-02-16	Schering Corporation	Extraction of interferon from bacteria
US4464355A (en) *	1981-03-26	1984-08-07	Hooper Trading Co.	Serum-free and mitogen-free T-cell growth factor and process for making same
US4448879A (en) *	1981-03-26	1984-05-15	Hooper Trading Company	High yield process for in vitro production of serum-free and mitogen-free interleukin-2
US4401756A (en) *	1981-04-14	1983-08-30	Immunex Corporation	Process for preparing human interleukin 2
JPS58116498A (ja) *	1981-12-28	1983-07-11	Takeda Chem Ind Ltd	Ｉｌ‐２をコードする新規伝令ｒｎａの製造法
US4450103A (en) *	1982-03-01	1984-05-22	Cetus Corporation	Process for recovering human IFN-β from a transformed microorganism
CA1341562C (en) *	1982-03-31	2007-11-27	Tadatsugu Taniguchi	Gene coded for interleukin-2 polypeptide, recombinant dna carrying the said gene, a living cell line possessing the recombinant dna, and method for producing interleukin-2 using the said cell
DE3377363D1 (en) *	1982-03-31	1988-08-18	Ajinomoto Kk	Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells
US4925919A (en) *	1984-04-25	1990-05-15	Roland Mertelsmann	Purified interleukin 2
US4778879A (en) *	1982-04-20	1988-10-18	Sloan-Kettering Institute For Cancer Research	Highly purified human interleukin 2 and method
EP0092163B1 (de) *	1982-04-20	1988-09-28	Sloan-Kettering Institute For Cancer Research	Reinigung von Interleukin-2
JPS58198293A (ja) *	1982-05-12	1983-11-18	Shionogi & Co Ltd	インタ−ロイキン等免疫調節因子の製造方法
US4490289A (en) *	1982-09-16	1984-12-25	Hoffmann-La Roche Inc.	Homogeneous human interleukin 2
US4462940A (en) *	1982-09-23	1984-07-31	Cetus Corporation	Process for the recovery of human β-interferon-like polypeptides
US4992271A (en) *	1982-09-23	1991-02-12	Cetus Corporation	Formulation for lipophilic IL-2 proteins
DE3242851A1 (de) *	1982-11-19	1984-05-24	Gesellschaft für Biotechnologische Forschung mbH (GBF), 3300 Braunschweig	Verfahren zur reinigung von menschlichen lymphokinen
JPS59116231A (ja) *	1982-12-13	1984-07-05	スロ−ン−ケツタリング・インステイテユ−ト・フオ−・キヤンサ−・リサ−チ	抗−インタ−ロイキン−２単クロ−ン抗体
US4512922A (en) *	1982-12-22	1985-04-23	Genentech, Inc.	Purification and activity assurance of precipitated heterologous proteins
US4511503A (en) *	1982-12-22	1985-04-16	Genentech, Inc.	Purification and activity assurance of precipitated heterologous proteins
US4511502A (en) *	1982-12-22	1985-04-16	Genentech, Inc.	Purification and activity assurance of precipitated heterologous proteins
AU579089B2 (en) *	1983-02-08	1988-11-17	Biogen, Inc.	Human interleukin-2-like polypeptides
ZA842025B (en) *	1983-03-21	1984-11-28	Hoffmann La Roche	Interleuken-2
GB8308483D0 (en) *	1983-03-28	1983-05-05	Health Lab Service Board	Secretion of gene products
US4582799A (en) *	1983-04-15	1986-04-15	Damon Biotech, Inc.	Process for recovering nonsecreted substances produced by cells
US4518584A (en) *	1983-04-15	1985-05-21	Cetus Corporation	Human recombinant interleukin-2 muteins
NZ208309A (en) *	1983-06-01	1988-04-29	Hoffmann La Roche	Recombinant leukocyte, fibroblast, or immune interferons (rifn-#a#, b or #g#) with one cys residue replaced
WO1985000606A1 (fr) *	1983-07-19	1985-02-14	Takeda Chemical Industries, Ltd.	Il-2 humaine et son procede de preparation
US4464295A (en) *	1983-08-17	1984-08-07	The United States Of America As Represented By The Secretary Of Agriculture	Simple and rapid method for extraction of proteins from bacteria
US4476049A (en) *	1983-09-20	1984-10-09	Hoffmann-La Roche Inc.	Method for the extraction of immune interferon
GB8327880D0 (en) *	1983-10-18	1983-11-16	Ajinomoto Kk	Saccharomyces cerevisiae
US4675383A (en) *	1983-11-15	1987-06-23	The Salk Institute For Biological Studies	Purification of T-cell growth factor
JPS60115528A (ja) *	1983-11-28	1985-06-22	Takeda Chem Ind Ltd	ヒトインタ―ロイキン―２蛋白質を含有する抗腫瘍用または免疫機能低下疾患治療用組成物
DK174501B1 (da) *	1983-12-23	2003-04-28	Hoffmann La Roche	Fremgangsmåde til fremstilling af interleukin-2
JPS61500790A (ja) *	1984-03-28	1986-04-24	シタス　コ−ポレイシヨン	微生物的に製造されたインターロイキン―２を含有する組成物
US4569790A (en) *	1984-03-28	1986-02-11	Cetus Corporation	Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US4530787A (en) *	1984-03-28	1985-07-23	Cetus Corporation	Controlled oxidation of microbially produced cysteine-containing proteins
EP0158198A1 (de) *	1984-03-29	1985-10-16	Takeda Chemical Industries, Ltd.	DNA und ihre Verwendung
DE3583880D1 (de) *	1984-04-09	1991-10-02	Takeda Chemical Industries Ltd	Stabile interleukin-2-zusammensetzung.
US4572798A (en) *	1984-12-06	1986-02-25	Cetus Corporation	Method for promoting disulfide bond formation in recombinant proteins
US4782139A (en) *	1985-10-28	1988-11-01	Eli Lilly And Company	Selective chemical removal of a protein amino-terminal residue
US4787658A (en) *	1986-07-29	1988-11-29	Harris Jr John	Unibody bumper system
US5156968A (en) *	1988-06-24	1992-10-20	Genentech, Inc.	Purified yeast ubiquitin hydrolase

1984
- 1984-03-28 US US06/594,223 patent/US4569790A/en not_active Expired - Lifetime
1985
- 1985-02-26 CA CA000475151A patent/CA1341083C/en not_active Expired - Lifetime
- 1985-03-25 PH PH32035A patent/PH21012A/en unknown
- 1985-03-25 IN IN220/CAL/85A patent/IN162903B/en unknown
- 1985-03-26 DK DK135985A patent/DK166324C/da not_active IP Right Cessation
- 1985-03-26 GR GR850741A patent/GR850741B/el unknown
- 1985-03-26 NZ NZ211569A patent/NZ211569A/en unknown
- 1985-03-27 NO NO851235A patent/NO851235L/no unknown
- 1985-03-27 FI FI851231A patent/FI94960C/fi not_active IP Right Cessation
- 1985-03-27 PT PT80172A patent/PT80172B/pt unknown
- 1985-03-27 EP EP85103649A patent/EP0156373B1/de not_active Expired - Lifetime
- 1985-03-27 DE DE3588189T patent/DE3588189T2/de not_active Expired - Lifetime
- 1985-03-27 EP EP91113235A patent/EP0470586B1/de not_active Expired - Lifetime
- 1985-03-27 ES ES541608A patent/ES8609362A1/es not_active Expired
- 1985-03-27 DE DE8585103649T patent/DE3586762T2/de not_active Expired - Lifetime
- 1985-03-27 IL IL74733A patent/IL74733A/xx not_active IP Right Cessation
- 1985-03-27 AT AT85103649T patent/ATE81674T1/de not_active IP Right Cessation
- 1985-03-28 IE IE79985A patent/IE59100B1/en not_active IP Right Cessation
- 1985-03-28 JP JP60062195A patent/JP2599903B2/ja not_active Expired - Lifetime
- 1985-03-28 ZA ZA852347A patent/ZA852347B/xx unknown
- 1985-03-28 AU AU40467/85A patent/AU592751B2/en not_active Expired
- 1985-03-28 KR KR1019850002078A patent/KR850007083A/ko not_active Ceased
1992
- 1992-05-06 US US07/879,753 patent/US5419899A/en not_active Expired - Lifetime
1995
- 1995-04-25 US US08/428,895 patent/US5614185A/en not_active Expired - Lifetime
1996
- 1996-05-15 JP JP8143485A patent/JP2648587B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
KR850007083A (ko)	1985-10-30
EP0470586B1 (de)	1998-07-15
AU4046785A (en)	1985-10-03
IN162903B (de)	1988-07-23
EP0156373A3 (en)	1987-09-02
CA1341083C (en)	2000-08-15
DK135985D0 (da)	1985-03-26
ES8609362A1 (es)	1986-09-01
PT80172A (en)	1985-04-01
FI94960B (fi)	1995-08-15
EP0470586A1 (de)	1992-02-12
DK135985A (da)	1985-09-29
IL74733A0 (en)	1985-06-30
AU592751B2 (en)	1990-01-25
HK1004474A1 (en)	1998-11-27
JP2648587B2 (ja)	1997-09-03
DK166324C (da)	1993-08-23
FI851231L (fi)	1985-09-29
DE3588189D1 (de)	1998-08-20
IE59100B1 (en)	1994-01-12
ES541608A0 (es)	1986-09-01
FI94960C (fi)	1995-11-27
DK166324B (da)	1993-04-05
GR850741B (de)	1985-06-26
PT80172B (pt)	1987-06-17
ZA852347B (en)	1986-11-26
ATE81674T1 (de)	1992-11-15
DE3586762T2 (de)	1993-02-25
US4569790A (en)	1986-02-11
IE850799L (en)	1985-09-28
US5614185A (en)	1997-03-25
DE3588189T2 (de)	1998-11-19
IL74733A (en)	1990-11-05
EP0156373A2 (de)	1985-10-02
JPH08332089A (ja)	1996-12-17
JPS611393A (ja)	1986-01-07
JP2599903B2 (ja)	1997-04-16
PH21012A (en)	1987-06-23
NZ211569A (en)	1988-05-30
DE3586762D1 (de)	1992-11-26
FI851231A0 (fi)	1985-03-27
EP0156373B1 (de)	1992-10-21
US5419899A (en)	1995-05-30

Publication	Publication Date	Title
NO851235L (no)	1985-09-30	Renset rekombinant interleukin-2 og fremstilling og rensing derav
EP0217645B1 (de)	1991-09-04	Stabile Formulierung biologisch aktiver Proteine zur parenteralen Injektion
US4931543A (en)	1990-06-05	Process for recovering microbially produced interleukin-2
US4604377A (en)	1986-08-05	Pharmaceutical compositions of microbially produced interleukin-2
Ejima et al.	1999	High yield refolding and purification process for recombinant human interleukin‐6 expressed in Escherichia coli
EP0206828A2 (de)	1986-12-30	Verfahren zur Gewinnung von reflektierenden, heterologe Proteine enthaltenden Teilchen aus mikrobiellen Wirtzellen und dessen Verwendung
DE3856203T2 (de)	1998-10-08	Produktion von gereinigtem, biologisch aktivem, bakteriell hergestelltem human-csf-1
EP0211835B1 (de)	1990-01-03	Pharmazeutische zusammensetzungen von mikrobenerzeugtem interleukin-2
US5162507A (en)	1992-11-10	Process for recovering purified, oxidized, renatured recombinant interleukin-2 from microorganisms
EP0210846B1 (de)	1992-03-11	Verfahren zum Extrahieren von Protein mittels organischer Säure
EP0368857B1 (de)	1997-08-06	Prozess zur gewinnung von gereinigtem, oxidiertem, renaturiertem, rekombinantem interleukin-2 aus mikroorganismen
AU631356B2 (en)	1992-11-26	Improved process for recovering microbially produced interferon-beta
JP2812760B2 (ja)	1998-10-22	微生物宿主から異種蛋白質を含有する屈折体を回収する方法
HK1004474B (en)	2000-03-17	Purified recombinant interleukin-2 compositions
CA1337671C (en)	1995-11-28	Process for recovering purified, oxidized, renatured recombinant interleukin-2 from microorganisms
CA1283356C (en)	1991-04-23	Pharmaceutical compositions of microbially produced interleukin-2